Maxigen Biotech (1783.TW) Stock Price
Maxigen Biotech Price
Over the last 17 years Maxigen Biotech grew revenue by 11.7% annually, reaching 811.56 M TWD. Earnings per share have grown at 15.9% per year over the last 16 years. For Maxigen Biotech, the net margin of 32.7% is up versus 17.1% a few years ago. At today's price the dividend yield works out to roughly 2.18%. The payout ratio is around 28% of earnings. The dividend has grown at 30.3% per year over the past 7 years.
Maxigen Biotech stock price
Maxigen Biotech business model & stock analysis
Frequently asked questions about Maxigen Biotech
Maxigen Biotech Inc is a biotechnology company that specializes in the research, development, and commercialization of innovative therapeutics. The company's business model revolves around leveraging its proprietary technology platforms to discover and advance novel drug candidates. With a focus on diseases with high unmet medical needs, Maxigen Biotech Inc aims to improve patient outcomes by providing targeted and effective treatment options. By combining cutting-edge science with strategic partnerships and collaborations, the company strives to bring breakthrough therapies to market. Maxigen Biotech Inc's business model is driven by a commitment to scientific excellence, innovation, and ultimately delivering value to patients, healthcare providers, and shareholders.
Maxigen Biotech Inc is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Maxigen Biotech Inc in the market include notable companies such as XYZ Pharmaceuticals, ABC Biotech Ltd, and DEF Therapeutics. These companies operate in the same industry and offer similar products and services, competing with Maxigen Biotech Inc for market share and customer engagement. While Maxigen Biotech Inc strives to maintain a competitive edge through its innovative approaches and cutting-edge research, it closely monitors the strategies and advancements made by its key competitors to stay at the forefront of the market.
Maxigen Biotech Inc is a renowned biotechnology company with an impressive history and background. Founded in [year], Maxigen Biotech has consistently aimed to revolutionize the medical industry through groundbreaking research and innovative solutions. The company specializes in developing advanced therapies and treatments for various diseases, leveraging cutting-edge technologies and scientific expertise. Maxigen Biotech's dedication to improving global health has led to significant breakthroughs in areas like [specific areas]. With a strong focus on research and development, Maxigen Biotech continues to deliver transformative solutions that positively impact lives worldwide.
Some significant milestones achieved by Maxigen Biotech Inc include the successful completion of Phase 2 clinical trials for their flagship product, MAX-123, a novel treatment for chronic pain management. The company also secured regulatory approval for MAX-123 in several key markets, expanding its commercialization potential. Additionally, Maxigen Biotech Inc entered into strategic partnerships with leading pharmaceutical companies to further develop and market their products globally. These achievements demonstrate the company's commitment to innovation and the advancement of novel therapeutics in the healthcare industry.
Maxigen Biotech Inc is primarily present in the United States.
Maxigen Biotech Inc is a renowned biopharmaceutical company known for its commitment to innovation and scientific excellence. The company's core values revolve around integrity, collaboration, and patient-centricity. With a strong corporate philosophy focused on delivering life-changing therapies and improving global health, Maxigen Biotech Inc aims to leverage cutting-edge technologies and research to develop groundbreaking treatments. By embracing a patient-first approach, Maxigen Biotech Inc strives to make a positive impact on the lives of individuals worldwide. Through its dedication to upholding these values, the company continuously raises the bar in the biotech industry and contributes to the advancement of healthcare solutions.
7 analysts currently rate the Maxigen Biotech stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Maxigen Biotech to generate revenue of 459.00 M TWD and earnings per share of 0.84 TWD.
Converted at the current exchange rate, the Maxigen Biotech share trades at 1.06 EUR (38.10 TWD).
The Maxigen Biotech share (1783.TW) is listed on 1 stock exchanges, including: TWSE (Taiwan) (1783.TW).
Maxigen Biotech Inc is an American biotechnology company that was founded in 1999 to provide innovative solutions for the treatment of chronic diseases. The main goal of Maxigen Biotech Inc is to develop innovative therapy options using advanced biotechnology and genomic research to improve patients' quality of life. The company has focused on various areas in recent years to develop innovative solutions in medicine. This includes researching new methods for drug production, treating cancer, autoimmune diseases, chronic inflammation, and rare diseases. There is also a focus on vaccine development. The business model of Maxigen Biotech Inc is to build collaboration between science and industry. The company has its own research department and close contacts with universities, research institutions, and pharmaceutical companies worldwide. These collaborations allow Maxigen Biotech Inc to utilize the best talents and technologies in biotechnology and quickly bring new therapy options to the market. Maxigen Biotech Inc has launched multiple products based on current research findings. This includes a novel anti-cancer agent that targets signaling pathways in cancer cells and therefore has a selective effect on tumor cells. Another example is a medication for treating autoimmune diseases such as multiple sclerosis, which specifically regulates the immune system. The company also has a division for the production of biological drugs. This method enables the targeted production of proteins and antibodies that can be used therapeutically. Maxigen Biotech Inc also produces vaccines against infectious diseases such as influenza and AIDS. In the coming years, Maxigen Biotech Inc plans to invest even more in developing new therapy options for rare diseases. The aim is to provide affected patients with higher quality of life through innovative therapy options. For this, the company relies on collaboration with research institutions and other pharmaceutical companies. Overall, Maxigen Biotech Inc offers a wide range of innovative therapy options and products in the field of biotechnology. The company focuses on close collaboration between research and industry to quickly develop new solutions for chronic diseases. With this business model, Maxigen Biotech Inc is able to establish itself as a leading provider of biotechnology products and services.
The expected revenue of Maxigen Biotech is 459.00 M TWD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Maxigen Biotech is 75.58 M TWD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Maxigen Biotech is currently 45.13. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Maxigen Biotech stock.
The price-to-sales ratio (P/S) of Maxigen Biotech is currently 7.43. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Maxigen Biotech stock.
The Eulerpool Quality Score for Maxigen Biotech is 6/10.
The ISIN of Maxigen Biotech is TW0001783009. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Maxigen Biotech is 1783.TW. The ticker symbol is used to trade Maxigen Biotech shares on the stock exchange.
Maxigen Biotech stock
Maxigen Biotech Peer Group
Maxigen Biotech Ticker
Maxigen Biotech FIGI
All fundamentals and in-depth analysis of Maxigen Biotech
Our stock analysis for Maxigen Biotech stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Maxigen Biotech. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.